Literature DB >> 18385756

Two cell lines of t(8;21) acute myeloid leukemia with activating KIT exon 17 mutation: models for the 'second hit' hypothesis.

H Becker, D Pfeifer, J D Afonso, S D Nimer, H Veelken, M Schwabe, M Lübbert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18385756     DOI： 10.1038/leu.2008.61

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

1.  Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.

Authors:  Ellen Weisberg; Chengcheng Meng; Abigail E Case; Martin Sattler; Hong L Tiv; Prafulla C Gokhale; Sara J Buhrlage; Xiaoxi Liu; Jing Yang; Jinhua Wang; Nathanael Gray; Richard M Stone; Sophia Adamia; Patrice Dubreuil; Sebastien Letard; James D Griffin
Journal:  Br J Haematol       Date:  2019-07-15       Impact factor: 6.998

2.  Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases.

Authors:  Lina Han; Jan Jacob Schuringa; André Mulder; Edo Vellenga
Journal:  Ann Hematol       Date:  2010-04-13       Impact factor: 3.673

3.  High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML.

Authors:  Yue Zhao; Qi Liu; Pankaj Acharya; Kristy R Stengel; Quanhu Sheng; Xiaofan Zhou; Hojoong Kwak; Melissa A Fischer; James E Bradner; Stephen A Strickland; Sanjay R Mohan; Michael R Savona; Bryan J Venters; Ming-Ming Zhou; John T Lis; Scott W Hiebert
Journal:  Cell Rep       Date:  2016-08-04       Impact factor: 9.423

4.  Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity.

Authors:  Kotaro Shirakawa; Lan Wang; Na Man; Jasna Maksimoska; Alexander W Sorum; Hyung W Lim; Intelly S Lee; Tadahiro Shimazu; John C Newman; Sebastian Schröder; Melanie Ott; Ronen Marmorstein; Jordan Meier; Stephen Nimer; Eric Verdin
Journal:  Elife       Date:  2016-05-31       Impact factor: 8.140

5.  RUNX1 Upregulates CENPE to Promote Leukemic Cell Proliferation.

Authors:  Shan Liu; Jianyu Yang; Guohuan Sun; Yawen Zhang; Cong Cheng; Jin Xu; Kuangyu Yen; Ting Lu
Journal:  Front Mol Biosci       Date:  2021-08-09

6.  Can SARS-CoV-2 induce hematologic malignancies in predisposed individuals? A case series and review of the literature.

Authors:  Bruno Almeida Costa; Kaiza Vilarinho da Luz; Sarah Emanuelle Viana Campos; Germison Silva Lopes; João Paulo de Vasconcelos Leitão; Fernando Barroso Duarte
Journal:  Hematol Transfus Cell Ther       Date:  2022-01-19

7.  Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia.

Authors:  W Jang; J-H Yoon; J Park; G D Lee; J Kim; A Kwon; H Choi; K Han; C H Nahm; H-J Kim; W-S Min; M Kim; Y Kim
Journal:  Blood Cancer J       Date:  2016-01-15       Impact factor: 11.037

8.  Molecular Genetic Characterization of Individual Cancer Cells Isolated via Single-Cell Printing.

Authors:  Julian Riba; Nathalie Renz; Christoph Niemöller; Sabine Bleul; Dietmar Pfeifer; Juliane M Stosch; Klaus H Metzeler; Björn Hackanson; Michael Lübbert; Justus Duyster; Peter Koltay; Roland Zengerle; Rainer Claus; Stefan Zimmermann; Heiko Becker
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240

9.  The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation.

Authors:  Natalia Martinez-Soria; Lynsey McKenzie; Julia Draper; Anetta Ptasinska; Hasan Issa; Sandeep Potluri; Helen J Blair; Anna Pickin; Asmida Isa; Paulynn Suyin Chin; Ricky Tirtakusuma; Daniel Coleman; Sirintra Nakjang; Salam Assi; Victoria Forster; Mojgan Reza; Ed Law; Philip Berry; Dorothee Mueller; Cameron Osborne; Alex Elder; Simon N Bomken; Deepali Pal; James M Allan; Gareth J Veal; Peter N Cockerill; Christian Wichmann; Josef Vormoor; Georges Lacaud; Constanze Bonifer; Olaf Heidenreich
Journal:  Cancer Cell       Date:  2018-10-08       Impact factor: 38.585

10.  Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.

Authors:  Ellen Weisberg; Chengcheng Meng; Abigail E Case; Hong L Tiv; Prafulla C Gokhale; Sara J Buhrlage; Jing Yang; Xiaoxi Liu; Jinhua Wang; Nathanael Gray; Sophia Adamia; Martin Sattler; Richard Stone; James D Griffin
Journal:  J Cell Mol Med       Date:  2020-01-22       Impact factor: 5.310
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.